CXCL9 and pneumonia: Since the treatment with CXCL9(74–103) decreased LPS-induced lung inflammation, as represented by reduced neutrophil recruitment and improved lung function, we next tested if the therapeutic treatment with CXCL9(74–103) would reduce lung inflammation and function in a model of pneumonia induced by K. pneumoniae.